Onyx Biotec Limited — Board Meeting, 28-05-2025: Outcome of Board Meeting

Onyx Biotec has announced a board meeting on the approval of the financial results for the quarter and half-year. Revenue hit ₹62 Cr with a net profit of ₹4.95 Cr, showing solid year-on-year growth. Operational costs remained stable while cash flow improved despite higher working capital. IPO proceeds of ₹25.38 Cr were used as planned, focusing on manufacturing upgrades, loan repayments, and corporate needs. The company holds a healthy cash balance of ₹8.61 Cr, underlining disciplined financial management after its IPO.